Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-42847922 crossover PSG study in major depressive disorder with insomnia
NL-OMON40706Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of seltorexant in Insomnia and major depressive disorder (MDD) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Latency to persistent sleep, Total sleep time and 3 more. Started Mar 2014; status: active, not recruiting.
02
Drugs
seltorexant
03
Conditions
Insomniamajor depressive disorder (MDD)
Beyond the preview
Go deeper on NL-OMON40706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40706.